Cordance Medical, a company developing a focused ultrasound system for brain diseases, has secured $8 in funding from investors. The capital will enable the company to advance its innovative platform designed to enhance precision medicine for neurological conditions.
The company's core technology centers on opening the blood-brain barrier (BBB) non-invasively, a crucial step for treating various brain ailments. This system facilitates precision medicine by allowing targeted drug delivery to specific brain regions, such as tumor sites or amyloid plaques. Cordance Medical’s method involves a simple, non-invasive 30-minute outpatient procedure, extending life by potentially accelerating drug approvals and enabling real-time insights into tumor biology through liquid biopsy tests. Pre-clinical and clinical investigations have already demonstrated the safety and efficacy of this focused ultrasound technology in opening the BBB. The company holds a strong intellectual property position, aiming for a painless, quick, and accessible product deployment for the community. Its platform has applications across a wide spectrum of conditions, including glioblastoma, brain metastasis, Alzheimer's, Parkinson's, epilepsy, and mental health.
This funding round is significant as it is designated to finance Cordance Medical through all essential pre-clinical activities. Successfully completing these stages is critical for the company as it prepares to initiate pivotal human studies next year. The investment directly supports the meticulous development required to bring this promising technology closer to clinical application.
The secured capital underscores the potential recognized by investors in Cordance Medical's approach to transforming treatment paradigms for complex brain diseases. Looking ahead, the company aims to leverage this funding to meticulously execute its pre-clinical roadmap, with the ultimate goal of progressing into human trials and ultimately delivering its innovative solution to patients in need.
